David Dai
Stock Analyst at UBS
(2.09)
# 2,911
Out of 5,173 analysts
37
Total ratings
37.5%
Success rate
-0.93%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Buy | $7 → $8 | $4.45 | +79.78% | 3 | Mar 18, 2026 | |
| SONY Sony Group | Downgrades: Market Perform | $30 → $22 | $20.22 | +8.80% | 2 | Mar 17, 2026 | |
| KURA Kura Oncology | Maintains: Buy | $16 → $15 | $8.26 | +81.60% | 4 | Mar 13, 2026 | |
| IOVA Iovance Biotherapeutics | Maintains: Neutral | $2 → $4 | $3.69 | +8.40% | 3 | Mar 5, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Buy | $90 → $128 | $77.91 | +64.29% | 1 | Mar 3, 2026 | |
| ASML ASML Holding | Maintains: Outperform | $1,528 → $1,642 | $1,317.25 | +24.65% | 2 | Jan 22, 2026 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $89.27 | +31.06% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $24.23 | +56.83% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $94.77 | +39.28% | 3 | Oct 31, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $8.75 | +128.57% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $26 | $14.43 | +80.18% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $15.51 | +93.42% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $12.74 | +88.38% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $29.91 | -19.76% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $14.06 | +390.75% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $32.75 | +52.67% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $65.08 | -7.81% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $6.92 | +6,373.99% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $60.92 | -34.34% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $2.86 | +1,298.60% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.14 | +2,236.45% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $27.27 | +90.69% | 1 | Mar 17, 2020 |
Perspective Therapeutics
Mar 18, 2026
Maintains: Buy
Price Target: $7 → $8
Current: $4.45
Upside: +79.78%
Sony Group
Mar 17, 2026
Downgrades: Market Perform
Price Target: $30 → $22
Current: $20.22
Upside: +8.80%
Kura Oncology
Mar 13, 2026
Maintains: Buy
Price Target: $16 → $15
Current: $8.26
Upside: +81.60%
Iovance Biotherapeutics
Mar 5, 2026
Maintains: Neutral
Price Target: $2 → $4
Current: $3.69
Upside: +8.40%
Kymera Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $90 → $128
Current: $77.91
Upside: +64.29%
ASML Holding
Jan 22, 2026
Maintains: Outperform
Price Target: $1,528 → $1,642
Current: $1,317.25
Upside: +24.65%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $89.27
Upside: +31.06%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $24.23
Upside: +56.83%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $94.77
Upside: +39.28%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $8.75
Upside: +128.57%
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $14.43
Upside: +80.18%
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $15.51
Upside: +93.42%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $12.74
Upside: +88.38%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $29.91
Upside: -19.76%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $14.06
Upside: +390.75%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $32.75
Upside: +52.67%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $65.08
Upside: -7.81%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $6.92
Upside: +6,373.99%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $60.92
Upside: -34.34%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $2.86
Upside: +1,298.60%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.14
Upside: +2,236.45%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $27.27
Upside: +90.69%